European equities traded in the US as American depositary receipts edged up late Wednesday morning with the S&P Europe Select ADR Index rising 0.1% to 1,896.24, erasing earlier declines.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and accommodations-booking company trivago (TRVG), which climbed 26% and 2.6%, respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and semiconductor company Sequans Communications (SQNS), which increased 2.5% each.
The decliners from continental Europe were led by brewing company Anheuser-Busch InBev (BUD) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which fell 2.9% and 1.8%, respectively. They were followed by lender Banco Santander (SAN) and biopharmaceutical company Grifols (GRFS), which were down 1.2% and 0.5%, respectively.
The gainers from the UK were led by biopharmaceutical companies NuCana (NCNA) and Akari Therapeutics (AKTX), which rose 2.7% and 2.1%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and oil and gas company BP (BP), which were up 1.8% and 1.3%, respectively.
The decliners from the UK and Ireland were led by biotech firms Autolus Therapeutics (AUTL) and Trinity Biotech (TRIB), which dropped 7.2% and 5%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and pharmaceutical company GSK (GSK), which decreased 2.9% and 2.6%, respectively.
